Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Government APCD Request for Data
|
|
|
- Amy McCoy
- 10 years ago
- Views:
Transcription
1 Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Government APCD Request for Data This form is to be used by all applicants, except Government Agencies, as defined in 957 CMR NOTE: In order for your application to be processed, you must submit the required application fee. Please consult the fee schedules for APCD data for the appropriate fee amount. A remittance form with instructions for submitting the application fee is available on the CHIA website. I. GENERAL INFORMATION APPLICANT INFORMATION Applicant Name: Title: Organization: Ashish K. Jha, MD, MPH K.T. Li Professor of International Health Harvard T.H. Chan School of Public Health Project Title: The relationship between opioid prescribing and opioid overdose Mailing Address: 677 Huntington Ave, Kresge 4 th floor, Boston, MA Telephone Number: Address: [email protected] Names of Co-Investigators: Laura Burke, Gideon Gil, Jie Zheng, Xiner Zhou, Robert Wild Addresses of Co-Investigators: [email protected]; [email protected]; [email protected] [email protected]; [email protected] Original Data Request Submission Date: February 24, 2015 Dates Data Request Revised: June 15, 2015 Project Objectives (240 character limit):. To examine the link between prescription opioid painkillers and abuse/overdose of both prescription and illicit opioids, such as heroin Project Research Questions (if applicable) 1. What percentage of Massachusetts patients prescribed an opioid painkiller are subsequently treated for opioid abuse, dependence, and overdose? 2. What percentage of Massachusetts patients treated for opioid abuse, dependence and overdose were previously prescribed an opioid painkiller? 3. Are certain doctors more likely than others to prescribe 1
2 opioids to a patient who subsequently receives treatment for opioid abuse, dependence or overdose? 4. Which patient-level factors are associated with opioid abuse, dependence and overdose? 5. To what extent are legitimate prescriptions of methadone and buprenorphine, drugs designed to combat opioid dependence, associated with subsequent opioid abuse, dependence, or overdose? 6. Do regions of Massachusetts with the higher levels of opioid prescribing have higher rates of treatment for opioid poisonings? II. PROJECT SUMMARY Briefly describe the purpose of your project and how you will use the requested CHIA data to accomplish your purpose. The purpose of this project is to provide health care professionals and policymakers with empirical data examining the relationship between prescription opioids and heroin abuse. We will use claims data from the Massachusetts All-Payer Claims database to determine the relationship between opioid prescriptions and subsequent opioid-related medical events (e.g. overdose or poisoning). We will also use the APCD data to characterize the types of patients and providers most involved in cases of opioid prescription with subsequent opioid poisoning event. Unlike some data sets which do not capture all payers and providers and may miss some prescriptions or heroin-related events of interest, the APCD s comprehensive data will allow us to identify the maximum possible number of such cases. III. FILES REQUESTED Please indicate the databases from which you seek data, and the year(s) of data requested. ALL PAYER CLAIMS DATABASE Single or Multiple Use Year(s) Of Data Requested Current Yrs. Available X Medical Claims Pharmacy Claims Dental Claims Member Eligibility Provider Product Single Use Multiple Use Single Use Multiple Use Single Use Multiple Use Single Use Multiple Use Single Use Multiple Use
3 Single Use Multiple Use APCD Release Version 3.0 Application Published IV. REQUESTED DATA ELEMENTS [APCD Only] State and federal privacy laws limit the use of individually identifiable data to the minimum amount of data needed to accomplish a specific project objective. Please use the APCD Data Specification Workbook to identify which data elements you would like to request and attach this document to your application. V. FEE INFORMATION Please consult the fee schedules for APCD data ) and Case Mix data, available at and select from the following options: APCD Applicants Only Academic Researcher Others (Single Use) Others (Multiple Use) Are you requesting a fee waiver? Yes No If yes, please submit a letter stating the basis for your request. Please refer to the fee schedule for qualifications for receiving a fee waiver. If you are requesting a waiver based on the financial hardship provision, please provide documentation of your financial situation. Please note that non-profit status alone isn t sufficient to qualify for a fee waiver. VI. MEDICAID DATA [APCD Only] Please indicate here whether you are seeking Medicaid Data: Yes No Federal law (42 USC 1396a(a)7) restricts the use of individually identifiable data of Medicaid recipients to uses that are directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Level 2 or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid data will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. Drug-related health events, especially overdose, are extremely costly to the Medicaid program. In 2009, the Substance Abuse and Mental Health Services Administration estimated that 3
4 Medicaid spends about $5 billion per year on substance use disorders. Beyond saving lives, reducing the number of opioid-related poisonings could thus save the Medicaid program a significant amount of money. Our proposal aims to deepen our understanding of one possible contributor to the substance abuse problem, prescription opioids. We hope that our findings allow policymakers to make informed decisions when crafting policies to address the problem of opioid-related heroin events. In order to study this phenomenon, our analytic team will need to track individual (de-identified) patients to link prescription drug records to any hospitalizations for drug-related events. VII. FILTERS If you are requesting APCD elements from Level 2 or above, describe any filters you are requesting to use in order to limit your request to the minimum set of records necessary to complete your project. (For example, you may only need individuals whose age is less than 21, claims for hospital services only, or only claims from small group projects.) APCD FILE Medical Claims Pharmacy Claims Dental Claims Membership Eligibility Provider Product DATA ELEMENT(S) FOR WHICH FILTERS ARE REQUESTED RANGE OF VALUES REQUESTED IX. PURPOSE AND INTENDED USE 1. Please explain why completing your project is in the public interest. We aim to explore the roots of the opioid abuse and dependence epidemic in Massachusetts by using the All Payer Claims Database to examine the link between the prescribing of opioid analgesic medications and subsequent opioid overdoses or poisonings. Studies from some other states and anecdotal evidence from Massachusetts suggest a large number of opioid abusers first became addicted to prescription opioids. But the extent to which prescription painkillers are associated with widespread opioid addiction, and the characteristics of patients who go on to use heroin, have not been well studied. We plan to determine the percentage of patients receiving emergency care and inpatient treatment for opioid overdoses who previously received opioid prescriptions. Furthermore, we will look at factors such as patient age, place of residence, and diagnosis, as well as the frequency, duration, and type of prescribed opioids, to find characteristics correlated with subsequent heroin abuse. We also will use the data to identify patterns of inappropriate opioid prescribing -- for example, multiple prescriptions obtained at the same time from more than one clinician -- and assess the contribution of overprescribing to the problem of heroin abuse. Published research from other places has found that a small percentage of clinicians is often responsible for the bulk of inappropriate opioid prescribing; one study showed that a small percentage of family physicians in Ontario wrote the final opioid prescription before death for 63 percent of patients whose 4
5 deaths involved opioids. We will explore whether a similar pattern exists in Massachusetts. To this last aim, we will also look at regions with the high levels of opioid prescribing to determine if there is an associated higher rate of opioid overdose. We will disseminate our findings widely by publishing them in the Boston Globe and on BostonGlobe.com. We also intend to publish these results in a peer-reviewed medical journal. 2. Attach a brief (1-2 pages) description of your research methodology. (This description will not be posted on the internet.) 3. Has your project received approval from your organization s Institutional Review Board (IRB)? Please note that CHIA will not review your application until IRB documentation has been received (if applicable). Yes, and a copy of the approval letter is attached to this application. No, the IRB will review the project on. No, this project is not subject to IRB review. No, my organization does not have an IRB. X. APPLICANT QUALIFICATIONS 1. Describe your qualifications to perform the research described or accomplish the intended use of CHIA data. The Principal Investigator for this proposal is Dr. Ashish K. Jha, MD MPH, Professor at the Harvard School of Public Health in the Department of Health Policy and Management. He has extensive experience studying healthcare costs, quality, and efficiency at the state and federal level, and is a nationally and internationally recognized expert on these topics. He also has extensive experience working with policymakers at many levels of government, which will help to ensure that our findings are communicated effectively with state officials who need this information. Co-Investigators for this project are Laura Burke, MD, MPH and Gideon Gil. Dr. Burke is an emergency medicine physician at Beth Israel Deaconess Medical Center and a research at the Harvard School of Public Health. She has experience in research involving large health care databases as well as clinical expertise in emergency medicine including the treatment of opioid poisoning. Gideon Gil has been the health and science editor for the Boston Globe since His staff has won numerous national awards, including the 2005 Pulitzer Prize for explanatory journalism. He previously was a medical reporter and editor at The Courier-Journal in Louisville, Ky. He studied biochemistry at Harvard College and journalism at Columbia University. He is currently a Knight Science Journalism Fellow at the Massachusetts Institute of Technology (MIT). The team will also include E. John Orav, PhD, a statistician at HSPH with whom this research team has worked on numerous prior projects. Dr. Orav will provide key input on analytic design, as well as on the appropriate interpretation of results. The team has worked together on many prior projects analyzing large databases to answer questions about variation in healthcare quality, variation in healthcare costs, and the types of hospitals that provide high-quality care at low costs, and is currently working together on a project examining highcost Medicare patients. The core research team will be assisted by data analysts and research assistants throughout the project s duration. 5
6 2. Attach résumés or curricula vitae of the applicant/principal investigator, key contributors, and of all individuals who will have access to the data. (These attachments will not be posted on the internet.) XI. DATA LINKAGE AND FURTHER DATA ABSTRACTION Note: Data linkage involves combining CHIA data with other databases to create one extensive database for analysis. Data linkage is typically used to link multiple events or characteristics that refer to a single person in CHIA data within one database. 1. Do you intend to link or merge CHIA Data to other datasets? X Yes No linkage or merger with any other database will occur 2. If yes, will the CHIA Data be linked or merged to other individual patient level data (e.g. disease registries, death data), individual provider level data (e.g., American Medical Association Physician Masterfile), facility level (e.g., American Hospital Association data) or with aggregate data (e.g., Census data)? [check all that apply] Individual Patient Level Data What is the purpose of the linkage: What databases are involved, who owns the data and which specific data elements will be used for linkage: Individual Provider Level Data What is the purpose of the linkage: What databases are involved, who owns the data and which specific data elements will be used for linkage: Individual Facility Level Data What is the purpose of the linkage: This will allow us to overlay hospital-level data to the analyses to learn how hospital structural characteristics (e.g. urban, teaching status, quality metrics, patient experience metrics) may be associated with opioid prescribing practices. The hospital with which an opioid prescriber is affiliated would be the data element used for linkage. 6
7 What databases are involved, who owns the data and which specific data elements will be used for linkage: 1. American Hospital Association (AHA) Annual Survey and information technology supplement. This database contains information about hospital size, ownership, teaching status, location, clinical resources (intensive care, surgical capability), proportion of Medicaid patients; presence and use of health information technologies including electronic health records. These data are owned by the American Hospital Association. In order to link APCD data to AHA data, we will crosswalk APCD variable MC077, National Billing Provider ID to AHA variable Provider Number (the identification number used by an institution to receive payment from Medicare & Medicaid). 2.Hospital Compare- is part of the Centers for Medicare & Medicaid Services (CMS) Hospital Quality Initiative which uses a variety of tools to help stimulate and support improvements in the quality of care delivered by hospitals. The intent is to help improve hospitals quality of care by distributing objective, easy to understand data on hospital performance, and quality information from consumer perspectives. The data is publicly available and allows us to look at hospital-level quality metrics such as concordance with recommended processes of care for acute myocardial infarction, heart failure, and pneumonia. These data are owned by CMS. In order to link APCD data to Hospital Compare data, we will crosswalk APCD variable MC077, National Billing Provider ID to Hospital Compare variable Provider Number (the identification number used by an institution to receive payment from Medicare & Medicaid). 3. Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey which contains hospital ratings on communication with clinical staff, pain control, hospital environment, receipt of discharge instructions. HCAHPS data are owned by CMS and the Agency for Healthcare Research and Quality (AHRQ). In order to link APCD data to HCAHPS data, we will crosswalk APCD variable MC077, National Billing Provider ID to HCHAPS variable Provider Number (the identification number used by an institution to receive payment from Medicare & Medicaid). 4. Impact File Local Medicare Wage Index, Disproportionate Share Index payments, teaching intensity, charge-to-cost ratios for individual hospitals. The Impact File data are owned by CMS. In order to link APCD data to Impact File data, we will crosswalk APCD variable MC077, National Billing Provider ID to Impact File variable Provider Number (the identification number used by an institution to receive payment from Medicare & Medicaid). Aggregate Data- What is the purpose of the linkage: We would like to investigate the demographic characteristics of regions that have high rates of opioid prescribing and/or opioid poisonings/overdose. Zip code will be used as the unit of linkage between APCD and the databases listed below. What databases are involved, who owns the data and which specific data elements will be used for linkage: 7
8 1. Area Health Resource File (AHRF) Population characteristics (age, racial makeup), poverty, income, physician and hospital supply. These data are owned by the federal Health Resources and Service Administration (HRSA). In order to link ZIP code information between APCD and AHRF, we will use: APCD variable MC 016 Member ZIP code for those analyses which define ZIP code based on patients residence, and APCD variable MC 035 Service Provider ZIP Code for those analyses which define ZIP code based on provider locations. We will use our internal database that contains all ZIP codes within each U.S. county to link these variables to the FIPS County Code variable in AHRF. 3. If yes, for each proposed linkage above, please describe your method or selected algorithm (e.g., deterministic or probabilistic) for linking each dataset. If you intend to develop a unique algorithm, please describe how it will link each dataset. We will use a deterministic linkage method for all datasets. 1. American Hospital Association (AHA) Annual Survey- We will link to AHA annual survey data using APCD variable MC077 National Billing Provider ID, which links to Provider Number in AHA data. 2.Hospital Compare- We will link to this dataset using APCD variable MC077 National Billing Provider ID, which links to Provider Number in Hospital Compare data. 3. Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey - We will link to this dataset using APCD variable MC077 National Billing Provider ID, which links to Provider Number in HCAHPS data4. Impact File We will link to this dataset using APCD variable MC077 National Billing Provider ID, which links to Provider Number in Impact File data. 5. Area Resource File (ARF) - We will link to this data set using Zip code, specifically APCD variable MC 016 Member ZIP code for those analyses which define ZIP code based on patients residence, and APCD variable MC 035 Service Provider ZIP Code for those analyses which define ZIP code based on provider locations. We will use our internal database that contains all ZIP codes within each U.S. county to link these variables to the FIPS County Code variable in AHRF. 4. If yes, please identify the specific steps you will take to prevent the identification of individual patients in the linked dataset. All patient data will only be linked in aggregate for example, if a patient is admitted to a hospital, we will link that hospital ID with information about that hospital s resources. There will be no additional patient-level data linked with the dataset. Furthermore, because patient ID is fully encrypted in APCD data, there is no way for the dataset to be linked to any other source that may pose a risk of identifying individual patients. 8
9 5. If yes, and the data mentioned above is not in the public domain, please attach a letter of agreement or other appropriate documentation on restrictions of use from the data owner corroborating that they agree to have you initiate linkage of their data with CHIA data and include the data owner s website. 9
10 XII. PUBLICATION / DISSEMINATION / RE-RELEASE 1. Describe your plans to publish or otherwise disclose CHIA Data, or any data derived or extracted from such data, in any paper, report, website, statistical tabulation, seminar, conference, or other setting. We expect specific deliverables at least one manuscripts in high-impact policy journals as well as dissemination of the findings for a report by the Boston Globe. Our proposed project has significant implications for the individuals and families impacted by the opioid epidemic, health care providers who may benefit from the knowledge of the impact of prescribing practices on this public health problem and policymakers who determine regulations governing health care. We believe that given the salience of the topic and the current governor s emphasis of this issue, it will be easy for us to reach out to key policymakers and clinical leaders to share our findings. 2. Will the results of your analysis be publicly available to any interested party? Please describe how an interested party will obtain your analysis and, if applicable, the amount of the fee. The results of our analysis will be available publicly only in the form of publications in highimpact policy journals, in the Boston Globe or at health policy conferences. 3. Will you use the data for consulting purposes? Yes X No 4. Will you be selling standard report products using the data? Yes X No 5. Will you be selling a software product using the data? Yes X No 6. Will you be reselling the data? Yes X No If yes, in what format will you be reselling the data (e.g., as a standalone product, incorporated with a software product, with a subscription, etc.)? 7. If you have answered yes to questions 3, 4 or 5, please describe the types of products, services or studies. 10
11 XIII. USE OF AGENTS AND/OR CONTRACTORS Third-Party Vendors. Provide the following information for all agents and contractors who will work with the CHIA Data. Company Name: Contact Person: Title: Address: Telephone Number: Address: Organization Website: 8. Will the agent/contractor have access to the data at a location other than your location, your off-site server and/or your database? Yes No If yes, please provide information about the agent/contractor s data management practices, policies and procedures in your Data Management Plan. 9. Describe the tasks and products assigned to this agent or contractor for this project. 10. Describe the qualifications of this agent or contractor to perform such tasks or deliver such products. 11. Describe your oversight and monitoring of the activity and actions of this agent or subcontractor. 11
12 XIV. ASSURANCES Applicants requesting and receiving data from CHIA pursuant to 957 CMR 5.00 ( Data Recipients ) will be provided with data following the execution of a data use agreement that requires the Data Recipient to adhere to processes and procedures aimed at preventing unauthorized access, disclosure or use of data, as detailed in the DUA and the applicant s CHIA-approved Data Management Plan. Data Recipients are further subject to the requirements and restrictions contained in applicable state and federal laws protecting privacy and data security, and will be required to adopt and implement policies and procedures designed to protect CHIA data in a manner consistent with the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA). By my signature below, I attest to: (1) the accuracy of the information provided herein; (2) my organization s ability to meet CHIA s minimum data security requirements; and (3) my authority to bind the organization seeking CHIA data for the purposes described herein. Signature: Printed Name: Title Ashish K. Jha Original Data Request Submission Date: February 24, 2015 Dates Data Request Revised: K.T. Li Professor of International Health 12
Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Government Agency Application for Data
Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Government Agency Application for Data This application is to be used by all applicants, except Government Agencies, as
Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Governmental Application for Case Mix Data
Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Governmental Application for Case Mix Data Case Mix Data Request Form Published 2.17.2015 This form is to be used by all
CHIA OVERVIEW OF THE MASSACHUSETTS ALL-PAYER CLAIMS DATABASE APRIL 2015 CENTER FOR HEALTH INFORMATION AND ANALYSIS
CENTER FOR HEALTH INFORMATION AND ANALYSIS OVERVIEW OF THE MASSACHUSETTS ALL-PAYER CLAIMS DATABASE APRIL 2015 CHIA INTRODUCTION The Center for Health Information and Analysis (CHIA) is a state agency charged
THE HIPAA PRIVACY RULE AND THE NATIONAL HOSPITAL CARE SURVEY
THE HIPAA PRIVACY RULE AND THE NATIONAL HOSPITAL CARE SURVEY Table of Contents I. Overview... 3 II. Legal Authority for NHCS... 3 III. Requirements of the HIPAA Privacy Rule... 3 IV. Extra Safeguards and
Federal Response to Opioid Abuse Epidemic
Healthcare Committee Federal Response to Opioid Abuse Epidemic On May 1, 20215 the Energy and Commerce Subcommittee on Oversight and Investigations held a hearing entitled What is the Federal Government
Substance Use: Addressing Addiction and Emerging Issues
MODULE 6: SUBSTANCE USE: ADDRESSING ADDICTION AND EMERGING ISSUES Substance Use: Addressing Addiction and Emerging Issues Martha C. Romney, RN, MS, JD, MPH Assistant Professor Jefferson School of Population
Revision to the Executive Director for Health Care Policy and Financing Rule Concerning the All-Payers Claims Database, Section 1.
STATEMENT OF BASIS AND PURPOSE 1. Summary of the basis and purpose for the rule or rule change. (State what the rule says or does and explain why the rule or rule change is necessary). These rules establish
Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District
Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse
Center for Medicare and Medicaid Innovation
Center for Medicare and Medicaid Innovation Summary: Establishes within the Centers for Medicare and Medicaid Services (CMS) a Center for Medicare & Medicaid Innovation (CMI). The purpose of the Center
For a Healthier America: Reducing Prescription Drug Misuse and Abuse
For a Healthier America: Reducing Prescription Drug Misuse and Abuse The misuse and abuse of prescription medicines is a growing public health problem. In addition to the tragic toll on families and communities,
Pennsylvania s ABC-MAP Program
Pennsylvania s ABC-MAP Program Recommendations on Best Practices ABC-MAP Governance Board Meeting May 20, 2015 Brandon C. Maughan, MD, MHS Marcus A. Bachhuber, MD University of Pennsylvania Philadelphia
HB 686-FN-A - AS INTRODUCED. establishing a single payer health care system and making an appropriation therefor.
0 SESSION -0 0/0 HOUSE BILL AN ACT -FN-A establishing a single payer health care system and making an appropriation therefor. SPONSORS: Rep. McNamara, Hills ; Rep. Suzanne Smith, Graf ; Rep. Moody, Rock
Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:
Section XX. Definitions. Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended (1) by striking clause (ii) and inserting the following: (ii) The term qualifying practitioner
Essential Hospitals VITAL DATA. Results of America s Essential Hospitals Annual Hospital Characteristics Survey, FY 2012
Essential Hospitals VITAL DATA Results of America s Essential Hospitals Annual Hospital Characteristics Survey, FY 2012 Published: July 2014 1 ABOUT AMERICA S ESSENTIAL HOSPITALS METHODOLOGY America s
Prescription Drug Monitoring Programs: Adopting Best & Promising PDMP Practices
Prescription Drug Monitoring Programs: Adopting Best & Promising PDMP Practices National Governors Association Policy Academy: Reducing Prescription Drug Abuse June 8, 2015 Burlington, VT Improving Interstate
SUPPORT PATH PROGRAM INTAKE FORM PHONE: 1-855-769-7284 FAX: 1-855-298-8700
SUPPORT PATH PROGRAM INTAKE FORM PHONE: 1-855-769-7284 FAX: 1-855-298-8700 1 REQUESTED SERVICE(S) (REQUIRED) CHECK ALL BOXES THAT APPLY Benefits Investigation Prior Authorization and Appeals Support Patient
HIPAA Privacy Rule CLIN-203: Special Privacy Considerations
POLICY HIPAA Privacy Rule CLIN-203: Special Privacy Considerations I. Policy A. Additional Privacy Protection for Particularly Sensitive Health Information USC 1 recognizes that federal and California
Prescription Drug Monitoring Programs: A State Policy to Address Prescription Opioid Poisonings. Michael Kim, MPH April 30, 2012
Prescription Drug Monitoring Programs: A State Policy to Address Prescription Opioid Poisonings Michael Kim, MPH April 30, 2012 Overview 1. Prescription Opioid Abuse and Poisoning 2. Prescription Drug
REQUEST FOR INDEPENDENT EXTERNAL REVIEW OF A HEALTH INSURANCE GRIEVANCE THROUGH THE OFFICE OF PATIENT PROTECTION
The Commonwealth of Massachusetts Health Policy Commission Office of Patient Protection 50 Milk Street, 8 th Floor Boston, MA 02109 (800)436-7757 (phone) (617)624-5046 (fax) REQUEST FOR INDEPENDENT EXTERNAL
Technical Note: Comparison of Methodologies between Total Health Care Expenditures and State Health Expenditure Accounts
Center for Health Information and Analysis Technical Note: Comparison of Methodologies between Total Health Care Expenditures and State Health Expenditure Accounts October 2014 Executive Summary This
HL7 & Meaningful Use. Charles Jaffe, MD, PhD CEO Health Level Seven International. HIMSS 11 Orlando February 23, 2011
HL7 & Meaningful Use Charles Jaffe, MD, PhD CEO Health Level Seven International HIMSS 11 Orlando February 23, 2011 Overview Overview of Meaningful Use HIT Standards and Meaningful Use Overview HL7 Standards
Attribute appropriate and inappropriate services to provider of initial visit
Optimal Care for Acute Low Back Pain - Adults Primary Care Description The rate represents the percentage of members ages 18 and older with newly diagnosed acute low back pain who received optimal care
Appendices to Interim Report on the Baltimore Buprenorphine Initiative. Managed Care Organization Information Pages
Appendices to Interim Report on the Baltimore Buprenorphine Initiative Appendix A Managed Care Organization Information Pages Appendix B Buprenorphine Online Physician Training Information Packet Appendix
MISSISSIPPI LEGISLATURE REGULAR SESSION 2016
MISSISSIPPI LEGISLATURE REGULAR SESSION 2016 By: Representative Mims To: Public Health and Human Services HOUSE BILL NO. 1187 1 AN ACT TO AMEND SECTION 73-25-34, MISSISSIPPI CODE OF 1972, 2 TO REVISE THE
SENATE... No. 2142. The Commonwealth of Massachusetts. In the Year Two Thousand Fourteen
SENATE.............. No. 2142 Tuesday, May 13, 2014 Text of the Senate Bill to increase opportunities for long-term substance abuse recovery (being the text of Senate, No. 2133, printed as amended). The
Limiting the Duration of Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt?
Limiting the Duration of Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt? Medicaid Evidence-Based Decisions Project June 25, 2014 Supported by National Institute
The Meaningful Use Stage 2 Final Rule: Overview and Outlook
The Meaningful Use Stage 2 Final Rule: Overview and Outlook Devi Mehta, JD, MPH Cand. 1 Taylor Burke, JD, LLM 2 Lara Cartwright-Smith, JD, MPH 3 Jane Hyatt Thorpe, JD 4 Introduction On August 23, 2012,
Business Associate Agreement
Business Associate Agreement This Agreement is entered into as of ("Effective Date"), between ( Covered Entity ), and ( Business Associate ). RECITALS WHEREAS, Business Associate provides services on behalf
CHIA METHODOLOGY PAPER MASSACHUSETTS TOTAL HEALTH CARE EXPENDITURES AUGUST 2015. center for health information and analysis
CENTER FOR HEALTH INFORMATION AND ANALYSIS METHODOLOGY PAPER MASSACHUSETTS TOTAL HEALTH CARE EXPENDITURES AUGUST 2015 CHIA INTRODUCTION Total Health Care Expenditures (THCE) is a measure that represents
Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs Montana State Fund 13 th Annual Medical Conference November 1, 2013 Peter Kreiner, Ph.D. PDMP Center of Excellence at Brandeis University Primary non-heroin opiates/synthetics
Strong States, Strong Nation POLICY OPTIONS TO DECREASE RISKS FROM THE USE OF METHADONE AS A PAIN RELIEVER
Strong States, Strong Nation POLICY OPTIONS TO DECREASE RISKS FROM THE USE OF METHADONE AS A PAIN RELIEVER November 17, 2015 Today s Speakers Karmen Hanson, Program Manager, NCSL Cynthia Reilly, Director,
2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov
OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion
Strategies for Electronic Exchange of Substance Abuse Treatment Records
Strategies for Electronic Exchange of Substance Abuse Treatment Records Patricia Gray, J. D., LL. M. Prepared for the Texas Health and Human Services Commission and the Texas Health Services Authority
HIPAA Privacy Rule Primer for the College or University Administrator
HIPAA Privacy Rule Primer for the College or University Administrator On August 14, 2002, the Department of Health and Human Services ( HHS ) issued final medical privacy regulations (the Privacy Rule
Co-Pay Assistance Program for CUBICIN (daptomycin for injection) for Intravenous Use Enrollment Form
1. PATIENT INFORMATION Name Gender: o Male o Female Date of Birth: / / Address City State ZIP Email Home Phone Cell Phone Work Phone Alternate Contact Person (Optional) Alternate Phone Number (Optional)
UNIVERSITY PHYSICIANS OF BROOKLYN, INC. POLICY AND PROCEDURE. No: Supersedes Date: Distribution: Issued by:
UNIVERSITY PHYSICIANS OF BROOKLYN, INC. POLICY AND PROCEDURE Subject: ALCOHOL & SUBSTANCE ABUSE INFORMATION Page 1 of 10 No: Prepared by: Shoshana Milstein Original Issue Date: NEW Reviewed by: HIPAA Policy
Health Care Costs from Opioid Abuse: A State-by-State Analysis
Health Care Costs from Opioid Abuse: A State-by-State Analysis M AT R I X G L O B A L A D V I S O R S, L L C April 0 The Centers for Disease Control has called prescription painkiller abuse an epidemic.
Please visit https://www.distributor.hcup-us.ahrq.gov/
KID APPLICATION KIT November 18, 2015 All HCUP Databases and select Supplemental Files may now be purchased online through the HCUP Central Distributor. Please visit https://www.distributor.hcup-us.ahrq.gov/
Concept Series Paper on Electronic Prescribing
Concept Series Paper on Electronic Prescribing E-prescribing is the use of health care technology to improve prescription accuracy, increase patient safety, and reduce costs as well as enable secure, real-time,
COMMONWEALTH of VIRGINIA
COMMONWEALTH of VIRGINIA Department of Medical Assistance Services HCBCS - Consumer Directed Service Coordination VIRGINIA MEDICAID PROVIDER ENROLLMENT PACKAGE Thank you for your interest in becoming a
Clinic/Provider Name (Please Print or Type) North Dakota Medicaid ID Number
Contract to Provide Health Management Services Supplementary Agreement Between The Department of Human Services, Medical Services Division (North Dakota Medicaid) and Clinic/Provider Name (Please Print
Department of Health and Human Services (HHS), Centers for Medicare & SUMMARY: In accordance with the requirements of the Privacy Act of 1974, we are
This document is scheduled to be published in the Federal Register on 08/17/2015 and available online at http://federalregister.gov/a/2015-20224, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program [email protected]. The West Virginia Model
West Virginia University School of Medicine BEHAVIORAL MEDICINE & PSYCHIATRY Morgantown, WV Carl R. Sullivan, M.D. Professor and Director Addictions Program [email protected] Disclosure Reckitt Benckiser
APPLICATION FOR GROUP TERM LIFE INSURANCE Underwritten by The United States Life Insurance Company in the City of New York (Herein called the Company)
APPLICATION FOR GROUP TERM LIFE INSURANCE Underwritten by The United States Life Insurance Company in the City of New York (Herein called the Company) Member information (Please print or type) Name APTA
PRESCRIPTION PAINKILLER OVERDOSES
IMPACT{ POLICY PRESCRIPTION PAINKILLER OVERDOSES National Center for Injury Prevention and Control Division of Unintentional Injury Prevention What s the Issue? In a period of nine months, a tiny Kentucky
SECTION 18 1 FRAUD, WASTE AND ABUSE
SECTION 18 1 FRAUD, WASTE AND ABUSE Annual FW&A Training Required for Providers and Office Staff 1 Examples of Fraud, Waste and Abuse 2 Fraud, Waste and Abuse Program Policy 3 Suspected Non-Compliance
Medicare Program: Expanding Uses of Medicare Data by Qualified Entities. AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
This document is scheduled to be published in the Federal Register on 07/07/2016 and available online at http://federalregister.gov/a/2016-15708, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
CHAPTER 114. AN ACT establishing a Medicaid Accountable Care Organization Demonstration Project and supplementing Title 30 of the Revised Statutes.
CHAPTER 114 AN ACT establishing a Medicaid Accountable Care Organization Demonstration Project and supplementing Title 30 of the Revised Statutes. BE IT ENACTED by the Senate and General Assembly of the
Data Breach, Electronic Health Records and Healthcare Reform
Data Breach, Electronic Health Records and Healthcare Reform (This presentation is for informational purposes only and it is not intended, and should not be relied upon, as legal advice.) Overview of HIPAA
HIPAA COMPLIANCE. What is HIPAA?
HIPAA COMPLIANCE What is HIPAA? The Health Insurance Portability and Accountability Act (HIPAA) also known as the Privacy Rule specifies the conditions under which protected health information may be used
CHAPTER 74. 1. Section 34 of P.L.1970, c.226 (C.24:21-34) is amended to read as follows:
CHAPTER 74 AN ACT concerning drug abuse, revising various parts of the statutory law, and supplementing P.L.2007, c.244. BE IT ENACTED by the Senate and General Assembly of the State of New Jersey: 1.
IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act
IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This
Hybrid Entities Health Insurance Portability and Accountability Act of 1996 (HIPAA)
Hybrid Entities Health Insurance Portability and Accountability Act of 1996 (HIPAA) 160.102 APPLICABILITY U.S. Department of Health and Human Services Office of the Secretary THE PRIVACY RULE Related Excerpts
Prescription Opioid Overdose & Misuse in Oregon
Prescription Opioid Overdose & Misuse in Oregon Mel Kohn, MD MPH Public Health Director and State Public Health Officer Oregon Health Authority Oregon In-State Policy Workshop NGA Policy Academy: Reducing
Workers Compensation Medicare Set-aside (WCMSA) Request & Worksheet
Workers Compensation Medicare Set-aside (WCMSA) Request & Worksheet Scope of Service If your workers compensation client is a Medicare beneficiary or has a reasonable expectation of being a Medicare beneficiary
Massachusetts Department of Public Health (MDPH) Prescription Monitoring Program (MA PMP) and Drug Control Program (DCP) April 8, 2014
MA PMP Pharmacy Data Entry and Data Submitter s FAQ Utilizing ASAP 4.2 Supplement to the MA PMP Pharmacy Data Entry and Data Submitter s Guide Utilizing ASAP 4.2 Massachusetts Department of Public Health
Drug Testing to Support Pain Management
NATIONAL REFERENCE LABORATORY Drug Testing to Support Pain Management 500 Chipeta Way, Salt Lake City, UT 84108 (800) 522-2787 (801) 583-2787 www.aruplab.com www.arupconsult.com ARUP is an enterprise of
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE May 19, 2012 National Association Boards of Pharmacy Annual Meeting Gil Kerlikowske, Director White House Office of National Drug Control Policy ONDCP
Fraud, Waste & Abuse. Training Course for UHCG Employees
Fraud, Waste & Abuse Training Course for UHCG Employees Overview The Centers for Medicare & Medicaid Services (CMS) require Medicare Advantage Organizations and Part D Plan Sponsors to provide annual fraud,
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
Drug overdose death rates by state per 100,000 people (2008) SOURCE: National Vital Statistics System, 2008
PRESCRITPION DRUG ABUSE: AN EPIDEMIC What is Addiction? By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Addiction is a primary, chronic disease
3/27/2012. Supply and Demand: The Substance Abuse/Misuse Market Triangle
Substance Abuse and Misuse: A Tragic Market That Can Be Curtailed Tennessee Department of Health Protect, promote, and improve the health and prosperity of persons in the State of Tennessee. John J. Dreyzehner,
APPLICATION FOR GROUP TERM LIFE INSURANCE Underwritten by The United States Life Insurance Company in the City of New York (Herein called the Company)
APPLICATION FOR GROUP TERM LIFE INSURANCE Underwritten by The United States Life Insurance Company in the City of New York (Herein called the Company) Member information (Please print or type) Name APTA
To: From: Date: Subject: Proposed Rule on Meaningful Use Requirements Stage 2 Measures, Payment Penalties, Hardship Exceptions and Appeals
MEMORANDUM To: PPSV Clients and Friends From: Barbara Straub Williams Date: Subject: Proposed Rule on Meaningful Use Requirements Stage 2 Measures, Payment Penalties, Hardship Exceptions and Appeals The
P U B L I C H E A L T H A D V I S O R Y
The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health 250 Washington Street, Boston, MA 02108-4619Tel: 617-624-6000 Fax: 617-624-5206 www.mass.gov/dph
NOTICE OF PRIVACY PRACTICES for the HARVARD UNIVERSITY MEDICAL, DENTAL, VISION AND MEDICAL REIMBURSEMENT PLANS
NOTICE OF PRIVACY PRACTICES for the HARVARD UNIVERSITY MEDICAL, DENTAL, VISION AND MEDICAL REIMBURSEMENT PLANS THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW
Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009 2010
Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009 2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence Service Officer Tennessee Department of
